Indications
Lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (PNA).
Composition
- Active substance
- moxetumomab pasudotox
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Lumoxiti
- Active substance
- moxetumomab pasudotox
- ATC code
- L01X
- Therapeutic area
- Leukemia, Hairy Cell
- Marketing authorisation holder
- AstraZeneca AB
- Status